Diffusion Pharmaceuticals Inc. found using ticker (DFFN) have now 1 analysts covering the stock. The analyst consensus points to a rating of ‘None’. The target price ranges between 3.5 and 3.5 with a mean TP of 3.5. Now with the previous closing price of 0.52 this is indicating there is a potential upside of 573.1%. The day 50 moving average is 0.39 while the 200 day moving average is 0.51. The company has a market capitalisation of $17m. Company Website: http://www.diffusionpharma.com
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.